Roche Says In CT-996 Phase 1 Trial, 4-Week Weight Loss Was 5.8% In Second-Best-Performing Cohort Vs 1.2% Weight Loss In Placebo Cohort; Placebo-Adjusted Average Weight Loss Of 6.1% From CT-996 Obesity Pill Trial Was From 1 Of 3 Active Cohorts In The Phase I Trial; In CT-996 Phase 1 Trial, 4-Week Weight Loss Was 7.3% In Best-Performing Cohort With 6 Patients Vs 1.2% Weight Loss In Placebo Cohort
Portfolio Pulse from Benzinga Newsdesk
Roche's CT-996 Phase 1 trial for an obesity pill showed promising results, with the best-performing cohort achieving a 7.3% weight loss over four weeks, compared to a 1.2% loss in the placebo group. The placebo-adjusted average weight loss was 6.1% in one of the active cohorts.
September 11, 2024 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roche's CT-996 obesity pill trial shows significant weight loss in Phase 1, with the best cohort losing 7.3% weight. This could positively impact Roche's stock as the results indicate potential for a successful obesity treatment.
The significant weight loss results from the CT-996 trial suggest a promising new obesity treatment, which could enhance Roche's product portfolio and market position. This is likely to positively influence investor sentiment and the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100